Haloperidol, Urine
Haloperidol is an antipsychotic compound that is used to treat the following mental illness disorders; psychotic symptoms of schizophrenia and Tourette’s syndrome. It belongs to the class of compounds known as butyrophenones. Schizophrenia is the main disorder that employs the use of antipsychotics for patient treatment. Schizophrenia is the most chronic major mental illness disorder in people under the age of 65.
Haloperidol is metabolized in the liver by the cytochrome 450 system, and reaches steady state plasma concentrations in 2-10 days. Haloperidol is readily absorbed from the GI tract in either a liquid or tablet preparation.
Haloperidol dosing is as follows:
Oral dose: 0.5-5 mg two to three times a day
IM dose: 2.5 mg every 4-8 hours
IV dose: 1-2 mg every 2-4 hours
The effects of haloperidol occur in 15-30 minutes after an IM administration or 30-60 minutes after an oral dose. Peak concentrations are reached within 2-6 hours after ingestion of an oral dose, and 20 minutes following an IM dose. Haloperidol is the most widely prescribed butyrophenone. The half-life of haloperidol is approximately 20 hours if given an oral dose. The adverse effects haloperidol varies from mild to life threatening depending on abuse. In general the adverse effects of these drugs are primarily non-neurologic in low doses and neurologic in high doses.
- Therapeutic monitoring
- Drug abuse evaluation
- Toxicity assessment
- Patient Compliance
Therapeutic levels: 5-16 ng/mL
Toxic levels: >50 ng/mL
Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.
Cut-Off Ranges
Cut-off values can vary based on the particular method of analysis that is used for detection by a quantitative method, such as LC/MS or GC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below.
Urine
Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.
Stability
- Ambient: 5 days
- Refrigeration: 7 days
- Frozen: 30 days
Serum
Serum specimens that are collected in a non-gel red top tube are the preferred specimens of choice. Specimens should be spun and the serum separated and refrigerated.
Stability
- Refrigeration: 7 days
- Frozen: 30 days
- Basalt RC (ed). Disposition of toxic drugs and chemicals in man, 7th ed. Foster City, CA: Biomedical Publications; 2004.
- Bell J. Methods for monitoring neuroleptic drugs. AACC Therapeutic Drug Monitoring and Toxicology. 1985;6:1-6.
- Levine B (ed). Principles of Forensic Toxicology, 4th ed. Washington DC: AACC Press. Chapter 24, Therapeutic Drugs III: Neuroleptics (Antipsychotics), 421-434; 2013.
- Balant-Gorgia A.E., Balant LP. Therapeutic drug monitoring of antidepressants. Clin Thera, 1992;14(4):612-4.
- Baselt RC (ed). Analytical procedures for therapeutic drug monitoring and emergency toxicology, 2nd ed. Littleton, MA: PSG Publishing Co.; 1987.
- Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 6th ed. Foster City, CA: Biomedical Publications; 2002.
- Fitzgerald R. Analytical toxicology of the benzodiazepines. AACC Therapeutic Drug Monitoring and Toxicology. 1995;16(7):169-79.
- Harman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds). Goodman and Gilman’s the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill Co.; 1996.
- Wians FH. Benzodiazepine update. AACC Therapeutic Drug Monitoring and Toxicology. 1989;11(4):7-20.
- Zherdev VP, Caccia S, Garattini S, Ekonomov AL. Species differences in phenazepam kinetics and metabolism. Euro J Drug Metab Pharm. 1982;7:191-6.